FDA grants fast-track status to Rebiotix's stool transplant

06/25/2013 | Minneapolis/St. Paul Business Journal

Rebiotix has received fast-track designation from the FDA for its fecal transplant, which could speed up marketing approval for the product. The Roseville, Minn.-based biotech startup intends to use the product for patients with Clostridium difficile, a type of hospital-acquired bacterial infection.

View Full Article in:

Minneapolis/St. Paul Business Journal

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY